HealthyPhase 1NCT00005673
Safety and Anti-HIV Activity of Capravirine Alone and in Combination With Other Anti-HIV Drugs
A Phase 1 study testing Capravirine in people with Healthy and HIV Infection, run by National Institute of Allergy and Infectious Diseases (NIAID) at 1 site in United States.
Trial summary
This 2-part study will test the safety and anti-HIV activity of capravirine alone, and the safety, anti-HIV activity, and drug interactions of capravirine combined with other anti-HIV drugs. Read more about this study
- Who is it for?
- Any ageHealthy volunteers can take part
- Conditions the study is for
- Healthy, HIV Infection
- What is being tested?
- Capravirine
- How many people
- 46 participants
- Where
- 1 siteUnited States
- Study dates
- May 2000to May 2002
- Phase
- Phase 1
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages Any age
- All sexes
- Healthy volunteers accepted
- Child, Adult, Older adult
CONTROL
Documented HIV-1 seronegative, confirmed by ELISA and Western blot.
Male or female, at least 18 years of age.
Laboratory values within established National Institute of Allergy and Infectious Diseases (NIAID) guidelines for participation in clinical studies.
Unremarkable physical exam
Signed written informed consent.
Must not use (or, depending on the agent, must not have used up to the last 28 days) of medications known to inhibit or induce cytochrome P450 during the initial period of the study period (Arm 1: Screening visit to Day 17; Arm 2: Screening visit to Day 15). After this initial period, use of these agents will be permitted on a case-by-case basis as per Investigator's clinical judgement; where necessary, additional PK studies may be performed. The prohibited medications include, but are not limited to: isoniazid, rifampin, rifabutin, astemizole, terfenadine, cisapride, cimetidine, triazolam, midazolam, quinidine, nifedipine, diltiazem, verapamil, amiodarone, or ergot alkaloids, carbamazepine, phenytoin and other hydantoins, phenobarbital and other barbiturates, propoxyphene, dexamethasone, oral contraceptives, antidepressants (fluoxetine, paroxetine, imipramine, amitriptyline, nefazodone), azole antifungals (ketoconazole, fluconazole, itraconazole) macrolide antibiotics (erythromycin, clarithromycin, dirithromycin), or grapefruit juice.
Must not use highly plasma protein bound drugs, including but not limited to , warfarin and phenytoin.
Must not be receiving treatment of chronic Hepatitis B infection with lamivudine (3TC).
Must not be using any antiretroviral therapy other than as indicated by the study regimen.
Must not have a history of significant allergy, hypersensitivity reaction, or adverse reactions to abacavir, efavirenz, or ritonavir.
Must be able to obtain venous access for sample collection.
Must not have any psychological/sociological condition or addictive disorder which would preclude compliance with the protocol.
Females must not be pregnant or lactating.
Must be willing to use adequate barrier contraception methods (other than oral contraceptives) if procreation potential exists.
PATIENT
Document HIV-1 seropositive, confirmed by ELISA and Western blot.
CD4 greater than 300/mm(3) and HIV-1 RNA viral load greater than 5,000 copies per mL.
Male or female, at least 18 years of age.
Adequate hematology (absolute neutrophil count greater than or equal to 1500/mm(3), platelets greater than or equal to 75,000/mm(3), hemoglobin greater than or equal to 9 g/dL).
Adequate renal function (serum creatinine less than or equal to 1.5 times upper-limit-of-normal [ULN]).
Adequate liver function (aspartate aminotransferase [AST/SGOT], alanine aminotransferase [ALT/SGPT] and total bilirubin less than or equal to 1.5 times ULN).
Signed written informed consent.
Must not have had any prior treatment with any non-nucleoside reverse transcriptase inhibitors.
Must not have a history of significant allergy, hypersensitivity reaction, or adverse reactions to abacavir or ritonavir.
Must not have evidence of clinical or genotypic resistance to abacavir.
Must not have an active uncontrolled infection.
Must not have unstable or severe concurrent medical conditions.
Must not have concomitant use of any antiretroviral therapy other than as indicated by the study regimen.
Must not have current treatment of chronic Hepatitis B with lamivudine (3TC).
Must not use (or, depending on the agent, must not have used up to the last 28 days) of medications known to inhibit or induce cytochrome P450 during the initial period of the study period (Screening visit to Day 14). After this initial period, use of these agents will be permitted on a case-by-case basis as per Investigator's clinical judgement; where necessary, additional PK studies may be performed. The prohibited medications include, but are not limited to: isoniazid, rifampin, rifabutin, astemizole, terfenadine, cisapride, cimetidine, triazolam, midazolam, quinidine, nifedipine, diltiazem, verapamil, amiodarone, or ergot alkaloids, carbamazepine, phenytoin and other hydantoins, phenobarbital and other barbiturates, propoxyphene, dexamethasone, oral contraceptives, antidepressants (fluoxetine, paroxetine, imipramine, amitriptyline, nefazodone), azole antifungals (ketoconazole, fluconazole, itraconazole) macrolide antibiotics (erythromycin, clarithromycin, dirithromycin), or grapefruit juice.
Must not have current use of highly plasma bound drugs, including but not limited to, warfarin and phenytoin.
Must not have current use, or use within the last 28 days, of any investigational agent.
Must not have cytotoxic chemotherapy, interferon treatment or radiation therapy within the last 28 days.
Must not have any psychological/sociological condition or addictive disorder which would preclude compliance with the protocol.
Females must not be pregnant or lactating.
Must be willing to use adequate barrier contraception methods (other than oral contraceptives) if procreation potential exists. (male or female)
Trial locations and contacts
1 site in 1 country.
United States1 site
National Institute of Allergy and Infectious Diseases (NIAID)
Bethesda, Maryland, 20892
About this study
Official title: Safety and Pharmacokinetic Study of Capravirine. Part I. Pharmacokinetics of Capravirine in HIV-Negative Volunteers. Part II. Antiviral Activity of Capravirine, Efavirenz, and Abacavir in HIV-Infected Patients
This 2-part study will test the safety and anti-HIV activity of capravirine alone, and the safety, anti-HIV activity, and drug interactions of capravirine combined with other anti-HIV drugs. Capravirine belongs to a class of drugs called non-nucleoside reverse transcriptase inhibitors (NNRTIs), which are effective when used together with other drugs, including nucleoside reverse transcriptase inhibitors (NRTIs) and protease inhibitors.
Normal volunteers 18 years of age and older may enroll in Part 1 of the study. HIV-infected patients 18 years of age and older who have not previously been treated with a NNRTI (efavirenz, nevirapine, and delavirdine) may participate in Part 2. All prospective study participants will be screened for eligibility with a physical examination, blood tests, a urine test and an electrocardiogram (ECG).
Read more
Part 1 - Volunteers will be randomly assigned to one of two treatment groups as follows:
Group 1 will receive capravirine alone for 7 days and capravirine plus efavirenz (another NNRTI) for an additional 10 days. On day 1, participants will have a physical examination, urine test and laboratory blood tests. Blood samples will be collected just before the first dose of capravirine is given and again at 0.5, 1, 2, 4, 6, 8 and 12 hours after the dose. A small plastic tube will be placed in a vein to avoid multiple needle sticks. On day 8, participants will have another physical examination and laboratory blood tests. Blood samples will be drawn again as described above. In the evening of day 8, efavirenz will be added to the regimen. On day 18 (the last day of the study), participants will have another physical examination and blood tests. Blood will again be collected as described above.
Group 2 will take capravirine alone for 8) days and capravirine plus ritonavir (a protease inhibitor) for an additional 8 days. Physical examinations, urine tests, and blood collections will be done as described above on day 1, day 8 and day 16 (the last day) of the study.
Part 2 - Patients will take capravirine alone for 7 days. On day 1, patients will have a physical examination, urine test and laboratory blood tests. Blood samples will be collected just before the first dose of capravirine is given and again at 0.5, 1, 2, 4, 6, 8 and 12 hours after the dose. A small plastic tube will be placed in a vein to avoid multiple needle sticks. On day 8, patients will have another physical examination and laboratory blood tests. Blood samples will be drawn again as described above. Additional drugs will then be added to the regimen (in varying doses according to group), as follows:
Group 1 - efavirenz plus abacavir
Group 2 - ritonavir plus efavirenz plus abacavir
Group 3 - ritonavir plus efavirenz plus abacavir
On day 15, the procedures performed on day 8 will be repeated.
Patients will have the option of having blood drawn daily on days 2 through 7 to measure HIV-1 viral load and of having a lumbar puncture (spinal tap) done between days 2 and 7 to measure how well capravirine gets into the central nervous system.
After day 15, patients in all groups will continue with their drug regimen until week 48 or until it is determined that the treatment is not effective for the patient. Physical examinations, viral load measurements, white blood cell counts and other blood tests will be done periodically throughout the trial. Within 4 weeks after the end of the study, patients will be followed with another physical examination, blood and urine tests, and an ECG.
Read the detailed description
This is an open-label, phase I study examining the safety and anti-HIV activity of an investigational non-nucleoside reverse transcriptase inhibitor, capravirine. The primary objectives of the study are 1) To evaluate the safety and pharmacokinetics of capravirine when combined with efavirenz and (low-dose) ritonavir in non-HIV-infected volunteers; 2) To evaluate the safety, virologic activity, and pharmacokinetics of capravirine when combined with efavirenz, (low-dose) ritonavir, and abacavir in HIV-infected patients; and 3) To evaluate the safety, virologic activity, and pharmacokinetics of a once-daily regimen with capravirine, efavirenz, (low-dose) ritonavir, and abacavir in HIV-infected patients. The study will be conducted in 2 parts. Part I will examine the safety, pharmacokinetics, and potential drug interactions of capravirine with other antiretroviral agents in non-HIV-infected volunteers. Sixteen volunteers (8 per group) will receive capravirine monotherapy (7 days), followed by the addition of either: 1) efavirenz (10 days); or 2) ritonavir (8 days). Part II will examine the safety, virologic activity, pharmacokinetics, and potential drug interactions of capravirine in HIV-infected patients. Thirty patients (10 per group) will receive of capravirine monotherapy (7 days), followed by the randomized addition of: 1) efavirenz/abacavir (7 days); 2) ritonavir/efavirenz/abacavir (7 days) twice-daily regimen; or 3) ritonavir/efavirenz/abacavir (7 days) once-daily regimen. [Doses of capravirine may be changed depending upon pharmacokinetic data obtained from Part I of the study.] The primary efficacy endpoint is the time-to-virologic-failure.
- Conditions
- Healthy, HIV Infection
- Being tested
- Capravirine
- Keywords
- HIV, Antiretroviral, NNRTI
- Medical subject headings
- HIV Infections
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
CapravirineDrug
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted25 May 2000 (estimated)
- Study startMay 2000
- Study completionMay 2002
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for HealthyStudies of the same condition, open and under way.
- More trials run by National Institute of Allergy and Infectious Diseases (NIAID)The sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase 1
- Primary purpose
- Treatment
- Enrolment
- 46 participants
Sponsor and investigators
- Sponsor type
- US National Institutes of Health
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT00005673
- Sponsor's protocol ID
- 000129
- Other IDs
- 00-I-0129
- Status last verified
- May 2002
- First submitted
- 24 May 2000
- Last updated
- 4 Mar 2008
- Results posted
- No
Study at a glance
From the registry record, last updated by the sponsor on 4 Mar 2008. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Safety and Pharmacokinetic Study of Capravirine. Part I. Pharmacokinetics of Capravirine in HIV-Negative Volunteers. Part II. Antiviral Activity of Capravirine, Efavirenz, and Abacavir in HIV-Infected Patients
- ClinicalTrials.gov ID
- NCT00005673
- Acronym / sponsor ID
- 000129
- Conditions
- Healthy, HIV Infection
- Keywords
- HIV, Antiretroviral, NNRTI
- Phase
- Phase 1
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 46 participants
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)US National Institutes of Health
- Study start
- May 2000
- Study completion
- May 2002
- First posted
- 25 May 2000 (estimated)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
This 2-part study will test the safety and anti-HIV activity of capravirine alone, and the safety, anti-HIV activity, and drug interactions of capravirine combined with other anti-HIV drugs. Capravirine belongs to a class of drugs called non-nucleoside reverse transcriptase inhibitors (NNRTIs), which are effective when used together with other drugs, including nucleoside reverse transcriptase inhibitors (NRTIs) and protease inhibitors.
Normal volunteers 18 years of age and older may enroll in Part 1 of the study. HIV-infected patients 18 years of age and older who have not previously been treated with a NNRTI (efavirenz, nevirapine, and delavirdine) may participate in Part 2. All prospective study participants will be screened for eligibility with a physical examination, blood tests, a urine test and an electrocardiogram (ECG).
Part 1 - Volunteers will be randomly assigned to one of two treatment groups as follows:
Group 1 will receive capravirine alone for 7 days and capravirine plus efavirenz (another NNRTI) for an additional 10 days. On day 1, participants will have a physical examination, urine test and laboratory blood tests. Blood samples will be collected just before the first dose of capravirine is given and again at 0.5, 1, 2, 4, 6, 8 and 12 hours after the dose. A small plastic tube will be placed in a vein to avoid multiple needle sticks. On day 8, participants will have another physical examination and laboratory blood tests. Blood samples will be drawn again as described above. In the evening of day 8, efavirenz will be added to the regimen. On day 18 (the last day of the study), participants will have another physical examination and blood tests. Blood will again be collected as described above.
Group 2 will take capravirine alone for 8) days and capravirine plus ritonavir (a protease inhibitor) for an additional 8 days. Physical examinations, urine tests, and blood collections will be done as described above on day 1, day 8 and day 16 (the last day) of the study.
Part 2 - Patients will take capravirine alone for 7 days. On day 1, patients will have a physical examination, urine test and laboratory blood tests. Blood samples will be collected just before the first dose of capravirine is given and again at 0.5, 1, 2, 4, 6, 8 and 12 hours after the dose. A small plastic tube will be placed in a vein to avoid multiple needle sticks. On day 8, patients will have another physical examination and laboratory blood tests. Blood samples will be drawn again as described above. Additional drugs will then be added to the regimen (in varying doses according to group), as follows:
Group 1 - efavirenz plus abacavir
Group 2 - ritonavir plus efavirenz plus abacavir
Group 3 - ritonavir plus efavirenz plus abacavir
On day 15, the procedures performed on day 8 will be repeated.
Patients will have the option of having blood drawn daily on days 2 through 7 to measure HIV-1 viral load and of having a lumbar puncture (spinal tap) done between days 2 and 7 to measure how well capravirine gets into the central nervous system.
After day 15, patients in all groups will continue with their drug regimen until week 48 or until it is determined that the treatment is not effective for the patient. Physical examinations, viral load measurements, white blood cell counts and other blood tests will be done periodically throughout the trial. Within 4 weeks after the end of the study, patients will be followed with another physical examination, blood and urine tests, and an ECG.
Detailed description
This is an open-label, phase I study examining the safety and anti-HIV activity of an investigational non-nucleoside reverse transcriptase inhibitor, capravirine. The primary objectives of the study are 1) To evaluate the safety and pharmacokinetics of capravirine when combined with efavirenz and (low-dose) ritonavir in non-HIV-infected volunteers; 2) To evaluate the safety, virologic activity, and pharmacokinetics of capravirine when combined with efavirenz, (low-dose) ritonavir, and abacavir in HIV-infected patients; and 3) To evaluate the safety, virologic activity, and pharmacokinetics of a once-daily regimen with capravirine, efavirenz, (low-dose) ritonavir, and abacavir in HIV-infected patients. The study will be conducted in 2 parts. Part I will examine the safety, pharmacokinetics, and potential drug interactions of capravirine with other antiretroviral agents in non-HIV-infected volunteers. Sixteen volunteers (8 per group) will receive capravirine monotherapy (7 days), followed by the addition of either: 1) efavirenz (10 days); or 2) ritonavir (8 days). Part II will examine the safety, virologic activity, pharmacokinetics, and potential drug interactions of capravirine in HIV-infected patients. Thirty patients (10 per group) will receive of capravirine monotherapy (7 days), followed by the randomized addition of: 1) efavirenz/abacavir (7 days); 2) ritonavir/efavirenz/abacavir (7 days) twice-daily regimen; or 3) ritonavir/efavirenz/abacavir (7 days) once-daily regimen. [Doses of capravirine may be changed depending upon pharmacokinetic data obtained from Part I of the study.] The primary efficacy endpoint is the time-to-virologic-failure.
Study design
- Primary purpose
- Treatment
Who may qualify
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Child, Adult, Older adult
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Capravirine | Drug | – |
Primary outcome
Not reported in the source record.
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 4 Mar 2008.
Related trials for Healthy
Recruiting
THE EFFECTS OF GAME-BASED EXERCISE PROGRAMS
Physical Activity, Body Image
Not yet recruitingPhase 1
A Phase I Study of GLR2053 Tablets in Chinese Healthy Adult Participants
Atopic Dermatitis
Recruiting
Colon-delivered Riboflavin and Gut Microbiota Composition
Microbiome Dysbiosis, Gut Health
Not yet recruiting
Neuroergonomic Analysis of a Brain-Computer Interface Device (BCI)
Healthy Volunteers - Male and Female
RecruitingPhase 1
First-in-Human Trial to Assess REGN20423 in Healthy Adult Participants and Adult Participants With Atopic Dermatitis
Healthy Volunteer, Atopic Dermatitis
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
The record lists no contact. Use the official record to reach the sponsor.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A Phase 1 study testing Capravirine in people with Healthy and HIV Infection, run by National Institute of Allergy and Infectious Diseases (NIAID) at 1 site in United States.
The full registered description is in the About this study section and the official record.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 4 Mar 2008. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in United States. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
What does this phase mean?
Phase 1 studies test a treatment in a small group of people for the first time or in a new way, mainly to check safety and find the right dose.
Not every study follows the same path, and some studies (observational studies, device studies) have no phase.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 4 Mar 2008; AzTrials last refreshed its copy on 8 Nov 2026.